In Depth 9 Dec 2025 When AI isn’t enough: How physics is shaping the next wave of drug discovery Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech – the AI and physics combo. December 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2025 Vandria reports VNA-318’s first-in-human data in Alzheimer’s Delve into Vandria’s technology and its Alzheimer’s candidate, VNA-318, the first mitophagy-based candidate in Alzheimer’s to reach the clinic. December 2, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Dec 2025 Stem cell therapy’s avant-garde: Eight companies leading the way Stem cell therapy has gained traction over the recent years and the market is growing, discover eight companies advancing the field. December 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2025 Swiss biotech going strong in 2025: 19 companies to put on your radar Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 19 promising Swiss biotech companies. November 12, 2025 - 20 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2025 AAVantgarde closes $141 million series B round to tackle inherited eye diseases Today AAvantgarde closes a $141 million series B round to advance its inherited eye diseases pipeline; find out more about its approach! November 3, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Oct 2025 The 11 most advanced microbiome players aiming for the gut Take a look at 11 of the top biotech companies working on the development of gut microbiome therapies to treat a range of diseases. October 28, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2025 The ESMO 2025 digest: Is oncology in good shape? The 2025 edition of the European Society for Medical Oncology (ESMO) was held this week in Berlin, delve into its key highlights. October 24, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing With Eli Lilly’s recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents. October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2025 NLS Days: How do things look for biotech in Sweden? As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden. October 17, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2025 Are European biotech VCs under pressure to scale? Time to get pragmatic As Asabys Partners has rolled Aliath Bioventures into its platform, it’s worth asking if European biotech VCs are under pressure to scale. October 9, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2025 AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). October 7, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2025 Asthma study suggests lung scarring may be reversible Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible. October 1, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email